2020 Conference Announcement, J Forensic Toxicol Pharmacol Vol: 8 Issue: 2
18th International Conference on Pharmacovigilence & Drug Safety Announcement of Pharmacovigilance-2020
Professor, Chemistry, California South University, USA, E-mail: Researcher.Scientist@gmail.com
Keywords: Forensic Criminology, Forensic Death Investigation
Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigil are (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.
Information received from patients and healthcare providers via pharmacovigilance agreements (PVAs), as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place. In fact, in order to market or to test a pharmaceutical product in most countries, adverse event data received by the license holder (usually a pharmaceutical company) must be submitted to the local drug regulatory authority.
Ultimately, pharmacovigilance is concerned with identifying the hazards associated with pharmaceutical products and with minimizing the risk of any harm that may come to patients. Companies must conduct a comprehensive drug safety and pharmacovigilance audit to assess their compliance with worldwide laws, regulations, and guidance
By analysing the importance of Pharmacovigilance & drug safety, Meetings International is organizing 18th International Conference on Pharmacovigilence & Drug Safety on August 26-27,2020 based on the theme “the development and testing of new medications". It Includes Data collection and verification, Coding of adverse reaction descriptions, Coding of drugs, Case causality assessment, timely reporting to authorities. The activity that is most commonly associated with pharmacovigilance (PV), and which consumes a significant amount of resources for drug regulatory authorities (or similar government agencies) and drug safety departments in pharmaceutical companies, is that of adverse event reporting. Adverse event (AE) reporting involves the receipt, triage, data entering, assessment, distribution, reporting (if appropriate), and archiving of AE data and documentation. The source of AE reports may include: spontaneous reports from healthcare professionals or patients (or other intermediaries); solicited reports from patient support programs; reports from clinical or post-marketing studies; reports from literature sources; reports from the media (including social media and websites); and reports reported to drug regulatory authorities themselves. For pharmaceutical companies, AE reporting is a regulatory requirement in most countries.
Pharmacovigilance 2019 has been concluded with the discussion on drug safety and Development, Pharmacovigilance Significance & Scope, Clinical Pharmacy and its Role in Treatment, Pre-Clinical and Clinical Trials, Biosimilars Pharmacovigilance and Risk Management, Clinical drug toxicity and biomarkers, Pharmacovigilance for herbal medicines, Pharmacoepidemiology, Serotonin pharmacology, Pharmacogenetics and pharmacogenomics and many more with the companionship of our Organizing Committee Members, Keynote Speakers, Oral and Poster Presenters. With the unique feedbacks from Pharmacovigilance 2019. It would like to announce the commencement 18th International Conference on Pharmacovigilence & Drug Safety on August 26-27, 2020 based on the theme “The development and testing of new medications”.
For more details, connect to